DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure.

Author(s): Colvin-Adams M, Taylor AL

Affiliation(s): Cardiac Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.

Publication date & source: 2007-03, Cleve Clin J Med., 74(3):227-34.

Publication type: Research Support, Non-U.S. Gov't; Review

The African American Heart Failure Trial (A-HeFT) found that African American patients with advanced heart failure fared better if the fixed-dose combination of isosorbide dinitrate and hydralazine was added to their regimen, which for most of them already included an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), a beta-blocker, and a diuretic (N Engl J Med 2004; 351:2049-2057). This placebo-controlled trial was the first to evaluate a therapy in a specific racial group, and it points the way to a more individualized approach to heart failure therapy.

Page last updated: 2007-05-03

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017